MSB 0.69% $1.46 mesoblast limited

Ruxolitinib passed FDA approval on poorer single arm study results than Ryconcil, page-4

  1. 2,410 Posts.
    lightbulb Created with Sketch. 33
    there is the Ace up the sleeve. Covid trial. A Hail Mary yes but a promising one.
    I
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.